Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-021706
Filing Date
2020-08-06
Accepted
2020-08-06 21:08:21
Documents
2
Period of Report
2020-08-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3007
2 EX-24 DOCUMENT attachment1.htm EX-24 4853
  Complete submission text file 0000899243-20-021706.txt   9262
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Issuer) CIK: 0001651431 (see all company filings)

EIN.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address
Wooldridge James (Reporting) CIK: 0001710641 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39425 | Film No.: 201083517